Structure Therapeutics' (GPCR) "Market Outperform" Rating Reiterated at JMP Securities

Structure Therapeutics (NASDAQ:GPCR - Get Free Report)'s stock had its "market outperform" rating reaffirmed by analysts at JMP Securities in a note issued to investors on Friday, Benzinga reports. They presently have a $91.00 price target on the stock. JMP Securities' price target suggests a potential upside of 154.05% from the company's previous close.

Several other brokerages have also commented on GPCR. Lifesci Capital restated an "outperform" rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Friday, May 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and an average price target of $85.71.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR traded down $2.83 during mid-day trading on Friday, hitting $35.82. 603,501 shares of the stock were exchanged, compared to its average volume of 560,903. Structure Therapeutics has a twelve month low of $21.79 and a twelve month high of $75.02. The company has a market cap of $1.67 billion and a P/E ratio of -43.16. The stock's fifty day simple moving average is $39.11 and its two-hundred day simple moving average is $46.20.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.04. As a group, equities research analysts predict that Structure Therapeutics will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Picton Mahoney Asset Management bought a new position in shares of Structure Therapeutics during the third quarter valued at approximately $116,000. Sectoral Asset Management Inc. bought a new stake in Structure Therapeutics during the fourth quarter valued at about $139,000. ADAR1 Capital Management LLC bought a new position in Structure Therapeutics in the fourth quarter worth about $163,000. China Universal Asset Management Co. Ltd. raised its holdings in Structure Therapeutics by 208.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company's stock worth $177,000 after purchasing an additional 2,939 shares in the last quarter. Finally, Washington University purchased a new stake in shares of Structure Therapeutics during the third quarter valued at about $215,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.